Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
Breast cancer prognostic tests are genomic tests which are used to determine a woman's risk of hormone receptor breast cancer recurrence as well as how likely she is to benefit from chemotherapy after breast cancer surgery and/or extended endocrine treatm
| Supplier | Identifier | Award Value | Cross-References |
|---|---|---|---|
| VERACYTE | - | £204,000 | - |